Adjuvant chemotherapy in early uterine sarcoma

Nine years' experience with early uterine sarcoma is reviewed. In addition to hysterectomy and radiotherapy, 34 patients received adjunctive chemotherapy; 67 patients received no adjunctive chemotherapy. Seventeen patients who received chemotherapy received combination vincristine, 1.5 mg/m2 weekly; actinomycin D, 0.5 mg intravenously on Days 1 to 5; and cyclophosphamide, 300 mg intravenously on Days 1 to 5. Seventeen other patients received adriamycin either alone at a dose of 50 mg/m2 BSA/month or in combination with vincristine and cyclophosphamide. Neither the probability of survival nor the disease-free interval was improved by the addition of adjuvant chemotherapy.